PET scanning and measuring the impact of treatment

Christian Cohade, Richard L. Wahl

Research output: Contribution to journalArticle

Abstract

Positron emission tomography (PET) scanning with F18-fluorodeoxyglucose or FDG is a becoming a standard method for tumor staging. The prediction and evaluation of therapy response are newer applications of FDG-PET. PET often offers an early read-out of treatment efficacy and is an attractive alternative to conventional anatomic assessments of treatment response. This article reviews the methods available with PET tomonitor therapy response. Disease specific applications of PET imaging are then reviewed. While FDG is the most commonly used radiotracer for PET, many other radioligands could be applied in the future.

Original languageEnglish (US)
Pages (from-to)119-134
Number of pages16
JournalCancer Journal
Volume8
Issue number2
DOIs
StatePublished - Apr 1 2002

Fingerprint

Positron-Emission Tomography
Neoplasm Staging
Fluorodeoxyglucose F18
Therapeutics

Keywords

  • Cancer
  • FDG
  • Fluorodeoxyglucose
  • PET
  • Positron emission tomography
  • Radionuclide imaging
  • Response
  • Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

PET scanning and measuring the impact of treatment. / Cohade, Christian; Wahl, Richard L.

In: Cancer Journal, Vol. 8, No. 2, 01.04.2002, p. 119-134.

Research output: Contribution to journalArticle

Cohade, Christian ; Wahl, Richard L. / PET scanning and measuring the impact of treatment. In: Cancer Journal. 2002 ; Vol. 8, No. 2. pp. 119-134.
@article{149cb3c2acd949d4b1065ba32f86870a,
title = "PET scanning and measuring the impact of treatment",
abstract = "Positron emission tomography (PET) scanning with F18-fluorodeoxyglucose or FDG is a becoming a standard method for tumor staging. The prediction and evaluation of therapy response are newer applications of FDG-PET. PET often offers an early read-out of treatment efficacy and is an attractive alternative to conventional anatomic assessments of treatment response. This article reviews the methods available with PET tomonitor therapy response. Disease specific applications of PET imaging are then reviewed. While FDG is the most commonly used radiotracer for PET, many other radioligands could be applied in the future.",
keywords = "Cancer, FDG, Fluorodeoxyglucose, PET, Positron emission tomography, Radionuclide imaging, Response, Therapy",
author = "Christian Cohade and Wahl, {Richard L.}",
year = "2002",
month = "4",
day = "1",
doi = "10.1097/00130404-200203000-00006",
language = "English (US)",
volume = "8",
pages = "119--134",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "0765-7846",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "2",

}

TY - JOUR

T1 - PET scanning and measuring the impact of treatment

AU - Cohade, Christian

AU - Wahl, Richard L.

PY - 2002/4/1

Y1 - 2002/4/1

N2 - Positron emission tomography (PET) scanning with F18-fluorodeoxyglucose or FDG is a becoming a standard method for tumor staging. The prediction and evaluation of therapy response are newer applications of FDG-PET. PET often offers an early read-out of treatment efficacy and is an attractive alternative to conventional anatomic assessments of treatment response. This article reviews the methods available with PET tomonitor therapy response. Disease specific applications of PET imaging are then reviewed. While FDG is the most commonly used radiotracer for PET, many other radioligands could be applied in the future.

AB - Positron emission tomography (PET) scanning with F18-fluorodeoxyglucose or FDG is a becoming a standard method for tumor staging. The prediction and evaluation of therapy response are newer applications of FDG-PET. PET often offers an early read-out of treatment efficacy and is an attractive alternative to conventional anatomic assessments of treatment response. This article reviews the methods available with PET tomonitor therapy response. Disease specific applications of PET imaging are then reviewed. While FDG is the most commonly used radiotracer for PET, many other radioligands could be applied in the future.

KW - Cancer

KW - FDG

KW - Fluorodeoxyglucose

KW - PET

KW - Positron emission tomography

KW - Radionuclide imaging

KW - Response

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0036516650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036516650&partnerID=8YFLogxK

U2 - 10.1097/00130404-200203000-00006

DO - 10.1097/00130404-200203000-00006

M3 - Article

C2 - 11999946

AN - SCOPUS:0036516650

VL - 8

SP - 119

EP - 134

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 0765-7846

IS - 2

ER -